Association of Tirzepatide versus Semaglutide with Risk of Asthma Exacerbation in Patients with Asthma and Type 2 Diabetes: A US Multicenter Retrospective Cohort Study.

Studied

A retrospective US study compared tirzepatide and semaglutide for asthma flare-ups in adults with asthma and type 2 diabetes.

Who / model

After matching, each group included 8176 adults, followed for 12 months. Time to the first asthma flare-up was the primary outcome.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

Flare-up rates were similar: 11.0% with tirzepatide versus 11.1% with semaglutide. Secondary analyses linked tirzepatide to less rescue-inhaler use, while systemic corticosteroid use was similar.

Limits

The authors call for randomized trials to clarify the role of these medicines in asthma.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary